BridgeMD
Combined impact of cardiovascular polypill treatment and a specific nurse education program on adherence to therapy in patients with ACS: a randomized study
EU CTIS ID: 2025-524751-32-00
What this study is testing
To evaluate, through a randomized controlled trial, the potential additive impact of prescribing the cardiovascular polypill at hospital discharge combined with the implementation of a nurse-led education program on therapeutic adherence one year after admission, in patients with acute coronary syndrome (ACS)
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patients admitted for acute coronary syndrome (ACS) at the study centers between September 2024 and September 2026. ACS will be defined as chest pain suggestive of ischemia accompanied by electrocardiographic changes indicative of myocardial ischemia (T-wave inversion, ST-segment elevation or depression, new onset left bundle branch block) and/or high-sensitivity troponin elevation above the laboratory reference threshold
You likely can't join if
- Contraindication to any of the components of the polypill
- Refusal or inability to provide informed consent
- Inability to complete clinical follow-up
- Patients admitted to long-term care facilities or nursing homes at the time of inclusion and/or during the one-year follow-up
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.